Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model
Squamous cell carcinoma of oral cavity (OCSCC) accounts for approximately 25% of cases of head and neck squamous cell carcinoma (HNSCC). Tobacco and alcohol consumption are the main risk factors for both cancers. Surgical resection, combined with adjuvant radiotherapy or radiochemotherapy in patient...
Main Authors: | Vanesa Gutiérrez Calderón, Alexandra Cantero González, Laura Gálvez Carvajal, Yolanda Aguilar Lizarralde, Antonio Rueda Domínguez |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-02-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920984061 |
Similar Items
-
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
by: Hirofumi Shibata, et al.
Published: (2021-09-01) -
Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer
by: R. Bryan Bell, et al.
Published: (2022-09-01) -
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
by: Joel Ho, et al.
Published: (2022-10-01) -
Neoadjuvant immunotherapy for resectable esophageal cancer: A review
by: Qing Li, et al.
Published: (2022-12-01) -
A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma
by: Udit Nindra, et al.
Published: (2023-05-01)